Douglas Roberts, MD
Rheumatology · Sacramento, CANPI 1083698062
Payments from drug & device makers
Across 1,227 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- Amgen$5K
- Johnson & Johnson$2K
- AbbVie$2K
- GSK$1K
- Pfizer$905
- plus $7K from 30 others
What the payments were for
- Consulting fees$2,79312%
- Food & beverage$19,69687%
- Education$2581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 118 | $4,716 |
| Amgen(2 entities) | 336 | $4,667 |
| Johnson & Johnson | 128 | $2,243 |
| AbbVie | 133 | $2,185 |
| GSK | 70 | $1,157 |
| Pfizer | 51 | $905 |
| Mallinckrodt Hospital Products Inc. | 47 | $748 |
| UCB, Inc. | 34 | $733 |
| E.r. Squibb & Sons, L.L.C. | 35 | $579 |
| Boehringer Ingelheim | 23 | $542 |
| Genentech USA, Inc. | 26 | $469 |
| Medexus Pharma, Inc. | 35 | $397 |
| Fresenius Kabi USA, LLC | 19 | $378 |
| ANI Pharmaceuticals, Inc. | 21 | $372 |
| Bristol Myers Squibb | 23 | $347 |
| AstraZeneca(2 entities) | 15 | $345 |
| Radius Health, Inc. | 14 | $329 |
| Hikma Pharmaceuticals USA | 19 | $231 |
| Antares Pharma, Inc. | 16 | $212 |
| Aurinia Pharma U.S., Inc. | 10 | $199 |
| Sanofi | 9 | $190 |
| Lilly USA, LLC | 13 | $180 |
| Mallinckrodt Enterprises LLC | 12 | $180 |
| Genentech, Inc. | 3 | $146 |
| Actelion Pharmaceuticals US, Inc. | 3 | $58 |
| Eyevance Pharmaceuticals LLC | 3 | $46 |
| Scilex Pharmaceuticals Inc. | 2 | $45 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Organon | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COSENTYX$2,793
How this compares
$22,747 in reported general payments places this provider in the 75th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 104 | $679,572 |
| Humira(Cf) PenAdalimumab | 86 | $672,612 |
| Enbrel SureclickEtanercept | 61 | $484,850 |
| Xeljanz XrTofacitinib Citrate | 59 | $412,597 |
| EnbrelEtanercept | 33 | $341,272 |
| Enbrel MiniEtanercept | 42 | $309,008 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 26 | $200,868 |
| SimponiGolimumab | 27 | $164,103 |
| Orencia ClickjectAbatacept | 22 | $121,804 |
| BenlystaBelimumab | 23 | $119,291 |
| OtezlaApremilast | 30 | $108,540 |
| Humira PenAdalimumab | 13 | $87,742 |
| Cimzia (2 Pack)Certolizumab Pegol | 13 | $71,785 |
| OtrexupMethotrexate/Pf | 31 | $37,880 |
| OlumiantBaricitinib | 13 | $34,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $2,185 | $679,572104 claims |
| AmgenEnbrel, Otezla | $4,667 | $449,81263 claims |
| Johnson & JohnsonSimponi | $2,243 | $164,10327 claims |
| GSKBenlysta | $1,157 | $119,29123 claims |
| UCB, Inc.Cimzia (2 Pack) | $733 | $71,78513 claims |
| Antares Pharma, Inc.Otrexup | $212 | $37,88031 claims |
| Lilly USA, LLCOlumiant | $180 | $34,70813 claims |
| Medexus Pharma, Inc.Rasuvo | $397 | $27,51935 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $45 | $7,57576 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 808 rheumatology providers in California.
Other rheumatology in Sacramento
- Samy MetyasCovina$12.9M
- Christine ThaiHuntington Beach$8.5M
- Tien-I SuWhittier$8.4M
- Eric LeeUpland$6.9M
- Orrin TroumSanta Monica$6.9M
- Shirley PangFullerton$5.7M
- William RobinsonStanford$5.1M
- Dan laTujunga$5.1M
- Christina Charles-SchoemanLos Angeles$4.8M
- Suneet GrewalWest Hollywood$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.